Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.

JAMA Oncology, 2016

755 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/d7303dd15189c2a62a5564a1587a2eb3cc5a944e

Citations in the corpus

• Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic (2018, neutral): “PD-L1 expression as a biomarker has demonstrated an inconsistent record of enriching for response to ICB, which is related to the dynamic and heterogeneous expression of PD-L1 in the tumor microenvironment, assay interpretation, and a lack of standardization across PD-L1 platforms [76], warranting t”